



Welcome to the latest edition of the SACT newsletter.

We release the newsletter at regular intervals in order to keep SACT colleagues up to date with any developments or new communications.

30 day mortality post-SACT

Overview

We have recently started sharing with the NHS trusts **two** new 30-day mortality post-systemic anti-cancer therapy (SACT) data releases; the Rapid Data Review (RDR) and the case-mix adjusted rates (CMAR) workbook. Both data releases have been designed to support NHS trusts with their 30-day mortality post-SACT review.

Please continue to contact the helpdesk to share your experiences, provide feedback or ask questions SACT@phe.gov.uk.

Case-mix adjusted rates (CMAR) workbook

We are pleased to announce that the 30-day mortality post-SACT workbook is now available on the SACT dataset website. This first workbook contains case-mix adjusted mortality rates for patients diagnosed between 2010 and 2017. We have included patients being treated for lung, gastric, pancreatic cancer, and cancer of unknown primary (CUP) in 2017-2018 (depending on the site), as reported by NHS trusts in England through their monthly routine SACT data uploads. This output is a deliverable of a major partnership between PHE and NHS England and NHS Improvement on SACT data.

Please [visit our website](#) to access the workbook, companion report, and FAQs.

We initially shared this workbook with NHS trusts in July, allowing each trust the opportunity to review the workbook and provide a statement to accompany their data. We have included these statements in the companion report.

Our next CMAR workbook containing patients being treated for ovary, bowel, breast & myeloma in 2018-2019 was shared with NHS trusts earlier this week. It will be publicly available on our website later this autumn.

Rapid Data Review (RDR) data feed

In July we shared the second Rapid Data review (RDR) quarterly report with NHS trusts which provides details of patients who died within 30 days of receiving SACT at their trust. The July release included patients who were treated January – March 2020 and aims to support trusts with their mortality and morbidity meetings. The next data feed will be sent in October to the agreed mortality contacts at each trust and will include patients treated April – June 2020.

SACT publications

Immunotherapy study

In August 2020, the 'International Journal of Cancer' published the pre-print release for our paper examining outcomes (including survival and toxicity) for patients prescribed immune checkpoint inhibitors, approved as first line therapy for metastatic melanoma in England. This is an important piece of work that demonstrates the value of the SACT database to assess the impact of new therapeutics. Head to their website to access the full study <https://doi.org/10.1002/ijc.33266>

The future of PHE

Most of you will be aware of the plans announced by Secretary of State The Rt Hon Matt Hancock MP to create a new [National Institute for Health Protection](#) (NIHP) 'to boost the UK's ability to deal with and recover from COVID-19'. The NIHP is due to be formally established and operating from Spring 2021. Plans for the other PHE functions including NDRS have not yet been agreed and we would like to reassure you all that NDRS will continue with business as usual across all areas.

The impact on the SACT dataset

We would like to confirm that the changes to PHE has had no impact on the SACT dataset. Please continue to submit your monthly data submissions and we will keep you updated on any developments going forward.

Helpdesk update

We would like to welcome our newest member to the team, Steven Potter. Steven is a Database Specialist with an impressive knowledge of internal databases and connection set ups and will continue his great work assisting internal staff members on accessing systems.

SACT v3 update

We understand that for various reasons, including the pandemic, there have been some delays to switching to SACT v3 submissions. The data liaison team will be working with these trusts to support progress. If you are ready to switch to SACT v3 submissions and have not yet done so, please complete the SACT v3 checklist available on our website www.chemodataset.nhs.uk and

CDF reports published on NICE website

The Final Appraisal Document for the CDF review of Osimertinib was published by NICE on 11/09/20. The treatment has been recommended by the Committee for routine use in metastatic NSCLC. The SACT report is included within the [committee papers](#) (p69), and the SACT data is also referenced in the company evidence submission and the Evidence Review Groups' independent critique of the evidence. The Final Appraisal Document for CDF review of Nivolumab for [previously treated squamous non-small-cell lung cancer](#) (p73) and for [previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer](#) (p138) was published on 17/09/20.

Upcoming releases

As part of the phase 2 partnership between PHE and NHSE-I, we have been commissioned to provide quarterly metrics for the chemotherapy Specialised Services Quality Dashboard (SSQD). The metrics presented on the dashboard will measure the quality and outcomes of services for each provider. The first release will be published in January 2021.

As always we welcome your feedback. Please send comments and suggestions for future newsletters to the SACT helpdesk SACT@phe.gov.uk

contact the helpdesk
SACT@phe.gov.uk.

SACT submissions

We would like to say a big thank you to trusts for catching up with submissions / continuing to submit data throughout the pandemic where possible. We have now re-initiated the escalation process for non-conformance. Please ensure your submissions are on time and within the SACT schedules. We will continue to send reminder emails for uploading and submitting files and to complete regimen mapping.

Outcomes update

All trusts are expected to start submitting the outcomes upload by the December 2020 deadline, **once they have switched to SACT v3.0**. Thank you to those who have started to submit their outcomes upload. It is important that trusts start this submission as soon as they can to allow time for the team to troubleshoot any issues. The outcomes upload is a subset of 18 items from the standard SACT upload, and aims to capture outcomes data which would normally be missed. This additional file should be submitted on a monthly basis following the same schedule as the standard SACT upload. More information is available on [the SACT website](#) and [the SACT dataset community](#), or you can contact the helpdesk for further details. We will continue to be in touch with trusts who have not yet started to send the outcomes upload as we approach the deadline.

Updated guidance

We have recently developed additional guidance for assessing treatment benefit for patients receiving non-curative treatments. The guidance has been produced and tested with the clinical community to ensure the details are clear and useful. We will share this guidance in September/October.

The outcomes working group

The outcomes working group met virtually in early September to discuss outcomes data collection and submission. 14 members of staff from a range of NHS trusts joined; we delivered several presentations and facilitated discussions which included the following:

- An update on progress with the outcomes upload, including challenges and data quality issues experienced so far
- Outcomes data collection, the challenges and best practice examples
- Outcomes focussed outputs and how these can be used

Presentations are available in the [community library](#); we will share learnings and new ideas from the discussions in due course.

The Cancer Drugs Fund (CDF) update

NICE National Institute for Health and Care Excellence

Since the last newsletter, we have been very busy with CDF reports and have provided NICE with six final reports in June and August. The last quarter of 2020 will be quieter, with one final report due, before the start of a new, busy year. As NICE committee reviews resume we expect to publish more reports, as part of final papers, in the coming months.

We will showcase the impact of SACT data on CDF reviews in an upcoming webinar (see "Data liaison update").

We are now supplying a list of treatments funded as

CancerStats2

COVID-19 dashboard

In June's newsletter we informed you of our plans to create a dashboard on [Cancerstats2](#) to understand the impact of COVID-19 on the oncology and haematology service. We can confirm that the dashboard is now available to access for all registered users. This dashboard is updated monthly to ensure you have the most up-to-date information.

Other reports

The next update for all other reports is due later this month and will display activity up until May 2020.

Please continue to send feedback on the reports and let us know if you have any suggestions on

SACT@phe.gov.uk.

part of the CDF [here](#). We hope this will provide trusts with additional time to review records and ensure CDF treatments are included in monthly SACT returns. We also shared an abbreviated version in August for treatments exiting the CDF soon.

Thank you for continuing to support the team by responding to emails and ensuring any missing data is sent to us to contribute to our analysis.

Important links

SACT website - www.chemodataset.nhs.uk

Portal registration -

www.cancerstats.nhs.uk/users/sign_up

Portal access - www.api.encore.nhs.uk/users/sign_in

CancerStats2 registration -

www.cancerstats.ndrs.nhs.uk/user/register

CancerStats2 report access -

www.cancerstats.ndrs.nhs.uk/

Data liaison update

Our data liaison team continue to support trusts over email and phone with on-going training, challenges, and data quality concerns. If you would like to arrange a catch up, please contact the helpdesk

SACT@phe.gov.uk.

Webinars

In July, we hosted an outcomes upload webinar with over 130 attendees. Thank you to everyone who joined; the slides and recording are available in the SACT dataset community.

The community is available for all NHS trust staff in England and can be accessed here www.khub.net/sact-dataset.

On the 8th October, we will be hosting a webinar designed for clinical members of staff, addressing questions that have previously been asked by these groups about the Cancer Drugs Fund (CDF). All staff members are welcome to join; please [click here](#) to register.

You have been sent this newsletter because you have previously expressed an interest in the SACT dataset. If you are happy to continue to receive this newsletter you do not need to do anything. If you do not wish to receive future SACT newsletters please email SACT@phe.gov.uk and let us know if you want to be removed from the newsletter circulation list and/or other SACT communications. *Alternatively you can [click the unsubscribe button below](#).*